CN104370880A - Protease inhibitor and preparing method and use thereof - Google Patents
Protease inhibitor and preparing method and use thereof Download PDFInfo
- Publication number
- CN104370880A CN104370880A CN201410031649.XA CN201410031649A CN104370880A CN 104370880 A CN104370880 A CN 104370880A CN 201410031649 A CN201410031649 A CN 201410031649A CN 104370880 A CN104370880 A CN 104370880A
- Authority
- CN
- China
- Prior art keywords
- compound
- ethanoyl
- represent hydrogen
- ethyl
- picolinoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 4
- -1 2-morpholinyl ethyl Chemical group 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 9
- 102000020233 phosphotransferase Human genes 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RGPBQGGBWIMGMA-BJMVGYQFSA-N 5-[(e)-[5-(4-bromophenyl)-6-hydroxy-3,6-dihydro-1,3,4-oxadiazin-2-ylidene]methyl]-1h-pyrimidine-2,4-dione Chemical compound OC1O\C(=C\C=2C(NC(=O)NC=2)=O)NN=C1C1=CC=C(Br)C=C1 RGPBQGGBWIMGMA-BJMVGYQFSA-N 0.000 description 1
- 0 CC(N)NC(C#N)=* Chemical compound CC(N)NC(C#N)=* 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000000547 effect on apoptosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 102000004898 mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a compound and a pharmaceutical composition, a preparation method and use thereof; and the present invention relates to a compound for reducing or inhibiting dual leucine zipper kinase activity of cells or subjects, and use of the compound and a solvate, a hydrate or a pharmaceutically acceptable salt of the compound in prevention or treatment of disease or related diseases caused by dual leucine zipper kinase disorders of patients.
Description
Technical field
The invention discloses a compounds and pharmaceutical composition thereof and its production and use, the present invention relates to a kind of reduction or the compound of two leucine zipper kinase activities of T suppression cell or experimenter, the illness using compound of the present invention or its solvate, hydrate or pharmacologically acceptable salt to cause because two leucine zipper kinases exception in prevention or treatment sufferer or the purposes of associated conditions.
Background technology
DLK (Dual Leucine zipper Kinase) is two leucine zipper kinases, has another name called MAPK upstream kinases or leucine zipper protein kinases.It is that Holzman equals find when screening mice develop regulation and control kinases and identify out for 1994, and containing 1 catalyst structure domain, 2 leucine-zipper motif and N end hold the structural domain of Gly/Pro-rich with C, can be phosphorylated at Ser, Thr place.DLK is at apoptosis, propagation, differentiation and tissue reconstruction important role.DLK inhibitor can give extraordinary action effect on apoptosis, propagation, differentiation and tissue reconstruction.
The present inventor has prepared one group of compound and similar compound thereof or its pharmacologically acceptable salt, and this group compound and similar compound thereof or its pharmacologically acceptable salt have beyond thought outstanding effect as DLK inhibitor.
Summary of the invention
The invention provides one group of compound and similar compound or its pharmacologically acceptable salt thereof the novelty teabag as DLK inhibitor.
Technical scheme of the present invention is as follows:
One compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein: R
1represent hydrogen, methyl; R
2represent hydrogen, methyl; R represent hydrogen, 2-methysulfonylethyl, 2-morpholinyl ethyl, 2-hydroxyethyl, 2-amino-ethyl, 2-cyano ethyl, carbamoyhnethyl, 2-picolyl, carboxymethyl, formamyl, 2-picolinoyl, 3-picolinoyl, 4-picolinoyl, ethanoyl, 2-dimethylamino acetyl, 2-hydroxyethylamino ethanoyl, 2-(
n-hydroxyethyl methylamino-) ethanoyl, 2-(2-imidazolyl) ethanoyl, 2,3-dihydroxyl propionyls.
Enumerate 3 preferred compounds below:
Compound (A), 4-cyano group-
n-[2-[3-[1-[2-(dimethylamino) ethanoyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide
；
Compound (B), 4-cyano group-
n-[2-[3-[1-[2-(methyl sulphonyl) ethyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide;
Compound (C), 4-cyano group-
n-[2-[3-[1-[2-morpholinyl ethyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide;
The synthetic route of compound of the present invention is as follows:
Wherein: R
1represent hydrogen, methyl; R
2represent hydrogen, methyl; R represent hydrogen, 2-methysulfonylethyl, 2-morpholinyl ethyl, 2-hydroxyethyl, 2-amino-ethyl, 2-cyano ethyl, carbamoyhnethyl, 2-picolyl, carboxymethyl, formamyl, 2-picolinoyl, 3-picolinoyl, 4-picolinoyl, ethanoyl, 2-dimethylamino acetyl, 2-hydroxyethylamino ethanoyl, 2-(
n-hydroxyethyl methylamino-) ethanoyl, 2-(2-imidazolyl) ethanoyl, 2,3-dihydroxyl propionyls.
Compound of the present invention is a kind of reduction or the compound of two leucine zipper kinase activities of T suppression cell or sufferer, the illness using compound of the present invention or its solvate, hydrate or pharmacologically acceptable salt to cause because two leucine zipper kinases exception in prevention or treatment sufferer or the purposes of associated conditions.
Compound of the present invention and analogue thereof or its pharmacologically acceptable salt can be prepared into through topical, gastrointestinal administration or the various preparations of parenteral administration.Described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.Described local administration preparation is powder injection, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc. through administrations such as organ, head, eyes.Described parenterals is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
The present inventor studies discovery: this compounds is as DLK inhibitor, and effect obviously.The exploitation of this new compound is by for going the disease for the treatment of to produce far reaching significance to applying DLK inhibitor future.
Accompanying drawing explanation
Fig. 1: the nuclear magnetic spectrum of compound (A).
Fig. 2: the nuclear magnetic spectrum of compound (B).
Fig. 3: the nuclear magnetic spectrum of compound (C).
Embodiment
preparation embodiment
The preparation of preparation embodiment 1(compd A and compd A 11)
Compd A 1 and A2 chemical combination generate compound A-13; A3 bromination obtains compd A 4; benzene replaces bromine and generates compound A-45; generate compd A 6 after deaminizing, nitro replaces generation compd A 7, and nitro is reduced generation compound A-28; under Boc protection; A8 is not generated compd A 9 by the amino-reactive that Boc protects, and trifluoroacetic acid takes off Boc and generates A10, and naphthene amino activation generates A11.
The preparation of preparation embodiment 2(compd B and compound B-11 1)
Compound B-11 and B2 chemical combination generate compd B 3; B3 bromination obtains compd B 4; benzene replaces bromine and generates compd B 5; generate compound B-26 after deaminizing, nitro replaces generation compd B 7, and nitro is reduced and generates compd B 8; under Boc protection; B8 is not generated compd B 9 by the amino-reactive that Boc protects, and trifluoroacetic acid takes off Boc and generates B10, and naphthene amino activation generates B11.
The preparation of preparation embodiment 3(Compound C and Compound C 11)
Compound C 1 and C2 chemical combination generate Compound C 3; C3 bromination obtains Compound C 4; benzene replaces bromine and generates Compound C 5; generate Compound C 6 after deaminizing, nitro replaces generation Compound C 7, and nitroreduction generates Compound C 8; under Boc protection; C8 is not generated Compound C 9 by the amino-reactive that Boc protects, and trifluoroacetic acid takes off Boc and generates C10, and naphthene amino activation generates C11.
Preparation containing compd A injection:
1. get common 50mg and 100mg formula (A) compound of N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer mix in water for injection and make it to dissolve;
2. mixing first uses 0.45um millipore filtration coarse filtration after dissolving after stable, then uses 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. procedural freeze-drying is carried out;
5. pyrogen, aseptic, the corresponding inspection such as visible foreign matters, particulate matter is carried out, stand-by after all meeting the requirements.
Preparation containing compd B injection:
1. get common 50mg and 200mg formula (B) compound of N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer mix in water for injection and make it to dissolve;
2. mixing first uses 0.45um millipore filtration coarse filtration after dissolving after stable, then uses 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. procedural freeze-drying is carried out;
5. pyrogen, aseptic, the corresponding inspection such as visible foreign matters, particulate matter is carried out, stand-by after all meeting the requirements.
Preparation containing Compound C injection:
1. get common 50mg and 400mg formula (C) compound of N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer mix in water for injection and make it to dissolve;
2. mixing first uses 0.45um millipore filtration coarse filtration after dissolving after stable, then uses 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. procedural freeze-drying is carried out;
5. pyrogen, aseptic, the corresponding inspection such as visible foreign matters, particulate matter is carried out, stand-by after all meeting the requirements.
effect example
By medicine A, B, the injection of C is configured to the concentration of 0.01mg/ml, roll up according to paper A small molecule – kinase interaction map for clinical(NATURE BIOTECHNOLOGY: 23, number of pages: 329-336, 2005), and paper Activation State-Dependent Binding of Small Molecule Kinase Inhibitors:Structural Insights from Biochemistry kinase inhibitors(Chemistry & Biology rolls up: 17, number of pages: 1241 – 1249, 2010) described method measures the IC50 of DLK, wherein each drug determination 5 times, average, the scope being included into DLK inhibitor IC50 according to mean values (is less than 0.01um, 0.01um-0.1um, 0.1um-0.2um, 0.2um-0.5um, 0.5um-1um).Wherein see the following form in the IC50 interval of each medicine:
Table one: the IC50 of each Drug inhibition DLK is interval.(IC50 averages after measuring 5 times)
| The IC50 scope of Drug inhibition DLK (unit: micro-rub) | Medicine A | Medicine B | Medicine C |
| Below 0.01um | |||
| 0.01um-0.1um | |||
| 0.1um-0.2um | |||
| 0.2um-0.5um | √ | √ | |
| 0.5um-1um | √ |
Claims (8)
1. a compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein: R
1represent hydrogen, methyl; R
2represent hydrogen, methyl; R represent hydrogen, 2-methysulfonylethyl, 2-morpholinyl ethyl, 2-hydroxyethyl, 2-amino-ethyl, 2-cyano ethyl, carbamoyhnethyl, 2-picolyl, carboxymethyl, formamyl, 2-picolinoyl, 3-picolinoyl, 4-picolinoyl, ethanoyl, 2-dimethylamino acetyl, 2-hydroxyethylamino ethanoyl, 2-(
n-hydroxyethyl methylamino-) ethanoyl, 2-(2-imidazolyl) ethanoyl, 2,3-dihydroxyl propionyls.
2. compound or pharmaceutically acceptable salt thereof according to claim 1 and analogue thereof, work as R
1, R
2represent hydrogen, R is when representing 2-dimethylamino acetyl, the various salt of this compound; Work as R
1, R
2represent hydrogen, R is when representing 2-methysulfonylethyl, the various salt of this compound; Work as R
1, R
2represent hydrogen, R is when representing 2-morpholinyl ethyl, the various salt of this compound.
3. compound or pharmaceutically acceptable salt thereof according to claim 1 and analogue thereof, it is selected from following compound:
Compound (A), 4-cyano group-
n-[2-[3-[1-[2-(dimethylamino) ethanoyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide
；
Compound (B), 4-cyano group-
n-[2-[3-[1-[2-(methyl sulphonyl) ethyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide;
Compound (C), 4-cyano group-
n-[2-[3-[1-[2-morpholinyl ethyl] piperidin-4-yl] phenyl] cyclohexenyl-1-base]-1
h-imidazoles-2-methane amide.
4. the preparation method of compound described in claim any one of claim 1-3, is characterized by and synthesize according to following route:
Wherein: R
1represent hydrogen, methyl; R
2represent hydrogen, methyl; R represent hydrogen, 2-methysulfonylethyl, 2-morpholinyl ethyl, 2-hydroxyethyl, 2-amino-ethyl, 2-cyano ethyl, carbamoyhnethyl, 2-picolyl, carboxymethyl, formamyl, 2-picolinoyl, 3-picolinoyl, 4-picolinoyl, ethanoyl, 2-dimethylamino acetyl, 2-hydroxyethylamino ethanoyl, 2-(
n-hydroxyethyl methylamino-) ethanoyl, 2-(2-imidazolyl) ethanoyl, 2,3-dihydroxyl propionyls.
5. compound described in any one of claim 1-4 or its solvate, hydrate, or its pharmaceutical salts and analogue thereof the purposes in the medicine of the two leucine zipper kinase inhibitor of preparation.
6. purposes according to claim 5, is characterized in that described compound is DLK inhibitor.
7. comprise the pharmaceutical composition of compound or pharmaceutically acceptable salt thereof any one of claim 1-6 and analogue thereof, it is characterized in that this pharmaceutical composition to be prepared into ordinary preparation, controlled release preparation or targeting preparation.
8. the pharmaceutical composition of claim 7, described compound and pharmacologically acceptable salt thereof are prepared into through topical with its analogue, gastrointestinal administration or the various preparations of parenteral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410031649.XA CN104370880A (en) | 2013-01-24 | 2014-01-23 | Protease inhibitor and preparing method and use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310036091X | 2013-01-24 | ||
| CN201310036091 | 2013-01-24 | ||
| CN201410031649.XA CN104370880A (en) | 2013-01-24 | 2014-01-23 | Protease inhibitor and preparing method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104370880A true CN104370880A (en) | 2015-02-25 |
Family
ID=52550115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410031649.XA Pending CN104370880A (en) | 2013-01-24 | 2014-01-23 | Protease inhibitor and preparing method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104370880A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1918162A (en) * | 2003-12-23 | 2007-02-21 | 赛福伦公司 | Novel fused pyrrolocarbazoles |
| CN101340909A (en) * | 2005-10-18 | 2009-01-07 | 詹森药业有限公司 | Method of inhibiting flt3 kinase |
| CN101437514A (en) * | 2004-10-22 | 2009-05-20 | 詹森药业有限公司 | Inhibidores of C-FMS cinasa |
| CN101610768A (en) * | 2006-04-20 | 2009-12-23 | 詹森药业有限公司 | Suppress the kinase whose method of C KIT |
| CN102573855A (en) * | 2009-10-22 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | Modulation of axon degeneration |
-
2014
- 2014-01-23 CN CN201410031649.XA patent/CN104370880A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1918162A (en) * | 2003-12-23 | 2007-02-21 | 赛福伦公司 | Novel fused pyrrolocarbazoles |
| CN101437514A (en) * | 2004-10-22 | 2009-05-20 | 詹森药业有限公司 | Inhibidores of C-FMS cinasa |
| CN101340909A (en) * | 2005-10-18 | 2009-01-07 | 詹森药业有限公司 | Method of inhibiting flt3 kinase |
| CN101610768A (en) * | 2006-04-20 | 2009-12-23 | 詹森药业有限公司 | Suppress the kinase whose method of C KIT |
| CN102573855A (en) * | 2009-10-22 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | Modulation of axon degeneration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6861764B2 (en) | Methods and compositions for promoting axonal regeneration and neural function | |
| ES2378999T3 (en) | Mimetics with calixarene-based peptide conformation, methods of use, and methods to obtain them | |
| CN111909155B (en) | Proteolysis targeting chimera, prodrug molecule for improving oral bioavailability of proteolysis targeting chimera and application of prodrug molecule | |
| JP2019508406A (en) | How to treat cancer | |
| US10759803B2 (en) | Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto | |
| ES2848710T3 (en) | New use of sigma-1 receptor agonist compounds | |
| US20220193053A1 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| CN104119340A (en) | Protease inhibitors, preparation method and application thereof | |
| CN117377663A (en) | Dicholatin derivatives that can be used to treat cancer | |
| CN101395143A (en) | Azaheterocyclic compounds for the treatment of malaria or AIDS | |
| CN104370880A (en) | Protease inhibitor and preparing method and use thereof | |
| CN106164059A (en) | With agedoite endopeptidase (AEP) inhibitor and the compositions related treatment to neurodegenerative diseases | |
| CN104387391A (en) | Protease inhibitor and preparation method and application thereof | |
| CN104119341B (en) | A kind of protease inhibitors and its production and use | |
| CN104370925A (en) | Protease inhibitor and preparing method and use thereof | |
| CN104370897A (en) | Protease inhibitor and preparing method and use thereof | |
| CN104151302A (en) | Protease inhibitor and preparing method and use thereof | |
| JP7108681B2 (en) | (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide A pharmaceutical composition comprising | |
| CN116139115A (en) | Application of magnolol and/or honokiol aromatic ring amino substituted derivatives in resisting hypoxia/anoxia injury and pharmaceutical composition | |
| US12194034B2 (en) | Neutrophil exocytosis inhibitors | |
| CN115477611B (en) | MRGPRX2 antagonists for the treatment of pseudoallergy | |
| US20230357349A1 (en) | Glucagon delivery via enzymatic actuation | |
| WO2011147999A1 (en) | Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses | |
| US20220133702A1 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| WO2018136933A1 (en) | Inhibition of stromal interaction molecule 1 (stim1) as a co-treatment for adult onset polycystic kidney disease (adpkd) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |
|
| RJ01 | Rejection of invention patent application after publication |